Clinical Trials Directory

Trials / Completed

CompletedNCT04197700

The PRESSURE CABG Cardiac Surgery Trial

PRotocolized vs pErsonalized Blood preSSUre peRi-operative paramEters in Coronary Artery Bypass Grafting Surgery: The PRESSURE CABG Cardiac Surgery Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
600 (actual)
Sponsor
University of Alberta · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will be a pragmatic, prospective, single-centre, unit-based cluster crossover, open-label registry trial. The cardiac surgical intensive care unit (CSICU) will be cluster assigned to alternating MAP targets in 6-month blocks in a sequence. Additional sites across Alberta may be added, as necessary.

Detailed description

Personalized Arm: The target MAP will be defined as +10% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements: * Pre-operative anesthesia or surgical consultation; * Other physician outpatient consultation (e.g. cardiology, family physician, internist) within 30 days of surgery; * Inpatient measurement the night before surgery; * Pre-anesthetic MAP The lower and upper safety limits of personalized MAP targets will be 50mmHg and \<90mmHg, respectively. Protocolized Arm: The target MAP will be defined as 65 +/- 5mmHg. Pharmacologic and fluid treatment decisions will be at the discretion of the most responsible physician. In both study arms, the blood pressure control period will extend from anesthetic induction until 12 hours after admission to the CSICU. As an additional safety metric, the anesthesiologist will be encouraged to utilize clinically-driven cerebral saturation monitoring to identify potential hypoperfusion. In cases with low bilateral saturations where the anesthesiologist feels low MAP may be the putative mechanism, the investigators will request that MAPs be raised in 5mmHg increments. Following completion of the study protocol, the MAP and/or systolic blood pressure targets will be at the discretion of the most responsible physician.

Conditions

Interventions

TypeNameDescription
OTHERTarget MAP ManagementTarget MAP Management

Timeline

Start date
2022-11-01
Primary completion
2024-05-01
Completion
2024-05-01
First posted
2019-12-13
Last updated
2024-09-19

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT04197700. Inclusion in this directory is not an endorsement.